MX2022003017A - Uso de un agonista del receptor de orexina 2 para tratamiento de somnolencia excesiva. - Google Patents

Uso de un agonista del receptor de orexina 2 para tratamiento de somnolencia excesiva.

Info

Publication number
MX2022003017A
MX2022003017A MX2022003017A MX2022003017A MX2022003017A MX 2022003017 A MX2022003017 A MX 2022003017A MX 2022003017 A MX2022003017 A MX 2022003017A MX 2022003017 A MX2022003017 A MX 2022003017A MX 2022003017 A MX2022003017 A MX 2022003017A
Authority
MX
Mexico
Prior art keywords
treatment
orexin
receptor agonist
excessive sleepiness
compound
Prior art date
Application number
MX2022003017A
Other languages
English (en)
Spanish (es)
Inventor
Deborah Hartman
Rebecca Evans
Helene Faessel
Shinichiro Tanaka
Robert Rubens
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2022003017A publication Critical patent/MX2022003017A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022003017A 2019-09-13 2020-09-12 Uso de un agonista del receptor de orexina 2 para tratamiento de somnolencia excesiva. MX2022003017A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900310P 2019-09-13 2019-09-13
US202063031687P 2020-05-29 2020-05-29
PCT/IB2020/058482 WO2021048821A1 (en) 2019-09-13 2020-09-12 Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness

Publications (1)

Publication Number Publication Date
MX2022003017A true MX2022003017A (es) 2022-06-14

Family

ID=72521681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003017A MX2022003017A (es) 2019-09-13 2020-09-12 Uso de un agonista del receptor de orexina 2 para tratamiento de somnolencia excesiva.

Country Status (11)

Country Link
US (1) US20220331303A1 (https=)
EP (1) EP4028003A1 (https=)
JP (1) JP2022547604A (https=)
KR (1) KR20220062361A (https=)
CN (1) CN114555083A (https=)
AU (1) AU2020347578A1 (https=)
BR (1) BR112022004576A2 (https=)
CA (1) CA3154320A1 (https=)
CO (1) CO2022004589A2 (https=)
MX (1) MX2022003017A (https=)
WO (1) WO2021048821A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4065585T3 (fi) 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
MX2022008392A (es) 2020-01-10 2022-08-08 Takeda Pharmaceuticals Co Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450.
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
AR130709A1 (es) 2022-10-07 2025-01-08 Kissei Pharmaceutical Compuesto de ciclopentano
TW202502342A (zh) * 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素2受體促效劑用於改善睡眠期間之呼吸功能的用途
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
JP2001500852A (ja) 1996-08-27 2001-01-23 プレーシス ファーマスーティカルズ インコーポレイテッド D―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
PL3411358T3 (pl) * 2016-02-04 2022-02-28 Takeda Pharmaceutical Company Limited Podstawiony związek piperydynowy i jego zastosowanie
JOP20190008A1 (ar) * 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
CA3154321A1 (en) * 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Tak-925 for use in treating narcolepsy

Also Published As

Publication number Publication date
KR20220062361A (ko) 2022-05-16
AU2020347578A1 (en) 2022-04-14
WO2021048821A8 (en) 2021-11-04
BR112022004576A2 (pt) 2022-06-14
JP2022547604A (ja) 2022-11-14
EP4028003A1 (en) 2022-07-20
US20220331303A1 (en) 2022-10-20
WO2021048821A1 (en) 2021-03-18
CN114555083A (zh) 2022-05-27
CA3154320A1 (en) 2021-03-18
CO2022004589A2 (es) 2022-04-29

Similar Documents

Publication Publication Date Title
MX2022003017A (es) Uso de un agonista del receptor de orexina 2 para tratamiento de somnolencia excesiva.
CL2022000027A1 (es) Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).
CL2021002880S1 (es) Estuche de auriculares. (divisional solicitud 202000595)
GEP20227443B (en) Magl inhibitors
MY209489A (en) Antibody against human il-4ra and use thereof
EP4616912A3 (en) Phosphoalkyl ribose polymers comprising biologically active compounds
ZA202106602B (en) Claudin 6 antibodies and uses thereof
MX2018015251A (es) Derivados de 2-amino-4-(amino sustituido)fenil carbamato fluorinado.
EP3768677A4 (en) COMPOSITIONS OF KV7 CHANNEL ACTIVATORS AND METHOD OF USE
MX2021002065A (es) Metodos, productos y usos relacionados con la depuracion de especies acidas de sulfuro.
CA3156474A1 (en) GPR52 MODULATING COMPOUNDS
EP4501404A3 (en) Solid pharmaceutical composition containing 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide
MX2022011077A (es) Variantes de transglutaminasa.
PH12022550937A1 (en) Pharmaceutical composition comprising selexipag
EP3902284A4 (en) EARPHONES WITH IN-EAR MICROPHONE
PH12022551241A1 (en) Egfr inhibitors
MX2020013170A (es) Composicion agricola.
EP3973550C0 (en) PEPTIDE IONOGEL, COMPOSITION, METHODS AND USES THEREOF
CL2022001361A1 (es) Composiciones antimicrobianas que comprenden arcilla modificada y copolímeros.
MX2010006509A (es) Formulaciones herbicidas para sales de trietanolamina de glifosato.
ZA200800328B (en) Ethanolamine salt on N-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4-oxadiazole-2-yl]phenyl)pyridine-3-sulphonamide
EP4007578A4 (en) SUBSTITUTED CYCLOPROPYL-2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGS THEREOF AND METHODS THEREOF
WO2021080931A8 (en) Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use
MX2021002067A (es) Metodos, productos y usos relacionados con la depuracion de especies acidas de sulfuro.
JP1704673S (ja)